NCT00645021View on ClinicalTrials.gov

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
ObesityHepatic Insufficiency
Interventions
DRUG

CP-945,598

Administration of CP-945,598 in subjects with mild hepatic function

DRUG

CP-945,598

Administration of CP-945,598 in subjects with moderate hepatic function

DRUG

CP-945,598

Administration of CP-945,598 in subjects with normal hepatic function

Trial Locations (2)

32809

Pfizer Investigational Site, Orlando

33169

Pfizer Investigational Site, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00645021 - Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug | Biotech Hunter | Biotech Hunter